Furthermore, research has identified mutations in various oncogenes and tumor suppressor genes, such as RAS and TP53 [9, 331–334], aberrant embryonic developmental signals, including the Wnt/β-catenin and Hippo signaling pathways [334–336], and specific gene variants such as the androgen receptor [337], as factors that influence the sensitivity of tumor cells to ferroptosis. This evidence concerns the gene TP53 and neoplasm.